Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The Danish pharmaceutical giant, which became Europe's most valuable company last year, said Wegovy sales jumped 106% in the first quarter.

Novo Nordisk Hikes Guidance as Weight-Loss Drug Sales Surge. Why the Stock's Falling.

Danish pharma giant Novo Nordisk raised its 2024 outlook and beat first-quarter profit expectations in its first-quarter earnings report Thursday morning, amid a frenzied rush to match booming consumer demand for its popular weight loss and diabetes drugs Ozempic and Wegovy.

Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug Frenzy

Novo Nordisk said its Wegovy injectable drug for weight loss now has more than 130,000 weekly prescriptions in North America alone after boosting supplies to meet insatiable demand.

Novo Nordisk now has more than 130,000 weight-loss prescriptions as it hikes financial outlook

This morning, pharmaceuticals reported triumphant Q1 2024 financial results before markets opened. One of the more memorable highlights was certainly the fact that Novo Nordisk's sales increased by 22% in Danish kroner (by 24% at constant exchange rates) to DKK 65.3 billion for the period.

Earnings report: Novo Nordisk cashes in on weight loss drug fever with better-than-expected results

Sales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.

Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than double

Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from Eli Lilly.

Obesity drugmaker Novo Nordisk's Q1 profit beats forecast

Bagsværd, Denmark, 2 May 2024 - financial report for the period 1 January 2024 to 31 March 2024 Operating profit increased by 27% in Danish kroner and by 30% at constant exchange rates (CER) to DKK 31.8 billion. Sales in North America Operations increased by 34% in Danish kroner (35% at CER).

Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024

Eli Lilly

Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease.

Wegovy, Mounjaro prices cut as British pharmacies compete for weight-loss patients

Bank of America

Mastercard

To paraphrase Rudyard Kipling, the secret to success in the stock market is to “keep your head when all about you are losing theirs.” When everyone is panicking and sending the market lower, that's the time for you to be cool as a cucumber and look for stocks to buy on dips.

Profit from the Panic: 3 Stocks to Pounce on When They Become Steals

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , said on Wednesday it plans to invest around $200 million in quantum computing startups.

Novo Nordisk owner to invest $200 million in quantum computing startups

Hermes International

TotalEnergies SE

UBS says investors should forget about the Magnificent Seven and look across the Atlantic to 18 European stocks they've highlighted that account for approximately 25% of the Stoxx Europe 600 Index, the exact weighting as the Mag 7 when initially conceived in 2023.  At least with the Mag 18, you have 18 choices rather than just seven.

3 of Europe's ‘Magnificent 18' Stocks That You Can Buy in the U.S.

AstraZeneca

GlaxoSmithKline

Teva Pharmaceutical

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.

FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic

AbbVie

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

Amgen

Moderna

Pfizer

Regeneron Pharmaceuticals

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Some of Novo Nordisk's popular weight loss drug Wegovy is back in stock in the U.S. after months of limited supplies, according to an update on the Food and Drug Administration's website, though shortages are set to continue as booming demand for obesity drugs still vastly outstrips Big Pharma's ability to ramp up production.

Wegovy Is Available Again After Shortages, FDA Says—But Supplies Are Still Limited

Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.

Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

The U.S. Food and Drug Administration website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy is available after being in short supply, while three other doses remained in limited availability due to increased demand.

One dose of Novo Nordisk's Wegovy back in supply, FDA website shows

UnitedHealth Group

Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs that can help diabetes and obesity, two significant health concerns around the world.

Forget Nvidia, These Unstoppable Stocks Are Better Buys

Novo Nordisk's weight loss drug, Wegovy, has received FDA approval for reducing the risk of major cardiovascular adverse events. Wegovy demonstrated a 20% reduction in the risk of major cardiovascular adverse events and a 19% reduction in the risk of all-cause death in the SELECT trial. The approval extends Novo Nordisk's leadership position in the obesity market and makes Wegovy eligible for Medicare coverage.

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Europe's biggest company, the Danish weight loss drug kingpin Novo Nordisk (NYSE:NVO)'s upcoming results will be squarely focused on the uptake of the flagship Wegovy drug in the US. Analysts have warned that the company risks undershooting forecasts due to Wegovy's slow uptake.

Novo Nordisk hopes to prove Wegovy naysayers wrong

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.

Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why

Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 a month for the same drug.

Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.

A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States.

US Senate committee investigates pricing of Novo's Ozempic and Wegovy

Intra-Cellular Therapies

Viking Therapeutics

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

News for Novo Nordisk Stock (NVO)